In short
Clinical trials are studying 64CU-PSMA I&T in men with newly diagnosed prostate cancer. These trials are looking at how well PET/CT scanning can find spread to pelvic lymph nodes before surgery. The main focus is diagnostic accuracy, especially sensitivity and specificity, in patients with unfavorable intermediate-risk, high-risk, or very high-risk disease.
Key points
- Clinical trials of 64CU-PSMA I&T are studying men with newly diagnosed prostate cancer. The main question is whether PET/CT scanning can detect pelvic lymph node spread before prostate surgery. Both trials are Phase 3 studies and focus on diagnostic accuracy, especially sensitivity and specificity. The target group includes pre-prostatectomy patients with unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer. One trial was withdrawn and one was completed. Each trial planned to enroll 323 participants.
Trial overview
Two interventional Phase 3 trials studied 64CU-PSMA I&T in men with newly diagnosed prostate cancer. Both trials used PET/CT, which is a combined scan used to look for possible cancer spread in the body.
The trials were designed to test the diagnostic performance of the scan, meaning how well it can find disease or show that disease is not present. The focus was on pelvic lymph node metastasis, which means cancer spread to lymph nodes in the pelvis.
Who was studied
The target group was pre-prostatectomy patients, meaning men being evaluated before prostate surgery. The trials specifically included men with unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer.
This group was chosen because the trials aimed to check whether the scan could find hidden spread to pelvic lymph nodes before surgery.
What the trials measured
The main outcomes were sensitivity and specificity of copper Cu 64 PSMA I&T PET/CT. Sensitivity checks how well the scan finds metastatic pelvic lymph nodes when they are truly present.
Specificity checks how well the scan shows that pelvic lymph nodes are not involved when they are truly negative. These outcomes were compared with histopathology, which is a microscope test of tissue and is used here as the reference standard.
Trial status and size
One trial was withdrawn, and the other was completed. Each trial planned an enrollment of 323 participants.
Both studies used the same phase, condition, and main outcome measures, so they appear to be closely related trial records.
How the imaging was judged
A true positive meant the PET scan showed at least one positive pelvic lymph node and histopathology also found a positive lymph node on the same side of the pelvis. A true negative meant the scan and histopathology both showed negative pelvic lymph nodes on the same side.
This patient-level approach was used to judge whether the scan could reliably detect or rule out lymph node spread before prostate surgery.